Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients.
Ramona Woitek, Mary A McLean, Stephan Ursprung...
https://pubmed.ncbi.nlm.nih.gov/34625424/Actively Recruiting
Led by Cambridge University Hospitals NHS Foundation Trust · Updated on 2022-11-14
780
Participants Needed
30
Research Sites
521 weeks
Total Duration
Researchers are studying breast cancer patients who have Triple Negative Breast Cancer TNBC andor a germline BRCA mutation gBRCA to see if adding olaparib, a PARP enzyme inhibitor, to platinum-based neoadjuvant chemotherapy is safe and improves the complete response rate at surgery. This is a randomized, open-label phase IIIII trial conducted in three stages, involving at least 780 patients, including 220 with gBRCA mutations. Participants receive at least 21 weeks of chemotherapy before surgery. Study groups include a control arm receiving paclitaxel and carboplatin, and two experimental arms where patients receive the same chemotherapy plus oral olaparib tablets taken twice daily during specified days of each 3-week cycle. Additional treatments such as prophylactic granulocyte-colony stimulating factor and anthracyclines are given as per local practice. Patients with residual disease after chemotherapy may join a sub-study with further treatments. During the trial, patients undergo screening tests including BRCA mutation testing, tumor marker assessments, and standard cancer staging. Researchers monitor treatment safety and effectiveness through pathological complete response rates, adverse events, survival outcomes, quality of life questionnaires, and imaging. Follow-up occurs for up to 10 years after surgery, with safety data regularly reviewed by independent committees to ensure participant well-being.
CONDITIONS
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
C
CCTC A Cambridge Cancer Trials Centre
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cambridge University Hospitals NHS Foundation Trust
Lead Sponsor
AstraZeneca
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Minimum of 21 weeks
Participants receive neoadjuvant chemotherapy with paclitaxel and carboplatin, with or without oral olaparib, over multiple cycles before surgery.
Weekly visits for up to 12 weeks during chemotherapy cycles
Duration - 1 to 2 weeks
Participants undergo surgery following completion of neoadjuvant chemotherapy.
1 surgery visit
Duration - Up to 10 years
Participants are followed up for safety, efficacy, and long-term outcomes including relapse and survival.
Regular follow-up visits as planned by the research team
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Ramona Woitek, Mary A McLean, Stephan Ursprung...
https://pubmed.ncbi.nlm.nih.gov/34625424/Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz...
https://pubmed.ncbi.nlm.nih.gov/40360463/Jean E Abraham, Karen Pinilla, Alimu Dayimu...
https://pubmed.ncbi.nlm.nih.gov/38588696/Cambridge University Hospitals NHS Foundation Trust
Lead Sponsor
AstraZeneca
Collaborating Sponsor